0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
This Week in JAMA |

This Week in JAMA FREE

JAMA. 2007;297(5):439. doi:10.1001/jama.297.5.439.
Text Size: A A A
Published online

ANTIBLEEDING AGENTS AND SURVIVAL FOLLOWING CABG

The perioperative safety of aprotinin, an antibleeding agent commonly used in cardiac surgery, was recently challenged. To investigate the long-term safety of aprotinin, Mangano and colleaguesArticle assessed all-cause mortality through 5 years of follow-up in patients who had coronary artery bypass graft (CABG) surgery and who received aprotinin, aminocaproic acid, tranexamic acid, or no antibleeding therapy. The authors found that patients who received aprotinin, but not those who received aminocaproic acid or tranexamic acid, had a significantly increased risk of death compared with patients who received no antibleeding agent. In an editorial, FergusonArticle discusses the use of observational data sets to assess the long-term safety of drugs and devices.

ECONOMIC RETURN OF PEDIATRIC EXCLUSIVITY TRIALS

Additional patent protection is granted to pharmaceutical companies conducting clinical trials to assess drug safety and efficacy in children (“pediatric exclusivity”). Whether the benefits to industry are disproportionate to the costs of the studies is not clear. In a cohort study of clinical trials conducted for pediatric exclusivity and submitted to the US Food and Drug Administration in 2002-2004, Li and colleagues quantified the trial costs and economic return to industry. The authors found considerable variability in the net economic return and the net return-to-costs ratio from the pediatric exclusivity trials, with some companies experiencing loss and others substantial economic benefit.

GENETIC VARIATIONS AND VENOUS THROMBOSIS IN WOMEN

Pathway proteins or enzymes that regulate hemostasis are well characterized, but the contribution of genetic variations in these components to the risk of venous thrombosis (VT) has not been fully investigated. Smith and colleaguesArticle conducted a population-based, case-control study in which they investigated the association of common genetic variations in 24 coagulation and fibrinolysis candidate genes with the risk of incident VT in postmenopausal women. Among the 280 single nucleotide polymorphisms (SNPs) analyzed, the authors identified 5 SNPs associated with VT risk. In an editorial, Dupuis and O’DonnellArticle discuss elements of study design and statistical considerations that are critical to the interpretation of large-scale studies of genetic associations.

STATINS, HDL-C, AND ATHEROSCLEROTIC PLAQUE REGRESSION

Statin therapy is associated with small increases in high-density lipoprotein cholesterol (HDL-C) levels, but whether statin-induced changes in HDL-C levels are reflected in reduced coronary artery atheroma volume is not known. Nicholls and colleagues report results of a post hoc analysis of data from patients enrolled in 4 prospective randomized trials of statin therapy and who had treatment-related atheroma volume change assessed with serial intravascular ultrasonography. The authors found that statin therapy was associated with regression of coronary artery atherosclerosis in patients whose low-density lipoprotein cholesterol levels were substantially reduced and whose HDL-C levels were increased by at least 7.5% above baseline levels.

CLINICIAN'S CORNER

Ms R is a 27-year-old woman who was diagnosed with polycystic ovarian syndrome (PCOS) during college. Legro discusses the diagnosis, pathophysiology, fertility-related issues, and treatment of PCOS.

A PIECE OF MY MIND

“All patients can be treated with respect and compassion—and thus be reassured that, at the very least, their physician cares about their welfare.” From “The Importance of the Right Heart.”

MEDICAL NEWS & PERSPECTIVES

A growing body of evidence indicates that cognitive-behavioral therapy can be effective for children with some mental illnesses.

HBA

Considerations and feasibility of hemoglobin A1c (HbA1c) thresholds as a measure of diabetes care quality.

BALANCING PRIORITIES

Reordering priorities in clinical practice, policy, and research to maximize health outcomes and control costs.

AUTHOR IN THE ROOM TELECONFERENCE

Join David Ganz, MD, MPH, February 21, 2007, from 2 to 3 PM eastern time to discuss The Rational Clinical Examination “Will My Patient Fall?” To register, go to http://www.ihi.org/AuthorintheRoom.

AUDIO COMMENTARY

Dr DeAngelis summarizes and comments on this week's issue. Go to http://jama.ama-assn.org/misc/audiocommentary.dtl.

JAMA PATIENT PAGE

For your patients: Information about polycystic ovary syndrome.

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.